[go: up one dir, main page]

WO2008149834A1 - ピリミドジアゼピノン誘導体 - Google Patents

ピリミドジアゼピノン誘導体 Download PDF

Info

Publication number
WO2008149834A1
WO2008149834A1 PCT/JP2008/060129 JP2008060129W WO2008149834A1 WO 2008149834 A1 WO2008149834 A1 WO 2008149834A1 JP 2008060129 W JP2008060129 W JP 2008060129W WO 2008149834 A1 WO2008149834 A1 WO 2008149834A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen atom
optionally substituted
group
pyrimidodiazepinone derivative
pyrimidodiazepinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060129
Other languages
English (en)
French (fr)
Inventor
Nobumasa Otsubo
Yukihito Tsukumo
Kenji Uchida
Yuichi Matsumoto
Kyoichiro Iida
Hidenori Takada
Fumitake Takizawa
Hitoshi Arai
Shuko Okazaki
Takamichi Imaizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to CN200880015414A priority Critical patent/CN101679447A/zh
Priority to EP08777080A priority patent/EP2163554B1/en
Priority to ES08777080T priority patent/ES2391549T3/es
Priority to JP2009517856A priority patent/JP5345931B2/ja
Priority to CA002689374A priority patent/CA2689374A1/en
Priority to US12/602,312 priority patent/US7998954B2/en
Publication of WO2008149834A1 publication Critical patent/WO2008149834A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　一般式（Ｉ） ［式中、ｎは１または２を表し、Ｚは水素原子などを表し、Ｒ１およびＲ２は、同一または異なって、水素原子などを表し、Ａは結合、（ＣＨ２）ｍ（式中、ｍは１～４の整数を表す）、置換基を有していてもよいフェニレン、置換基を有していてもよいピリジンジイル、またはＣ＝Ｏを表し、Ｒ３は水素原子、置換基を有していてもよい低級アルキルなどを表し、Ｒ４は水素原子などを表す］で表されるピリミドジアゼピノン誘導体またはその薬学的に許容される塩などを提供する。
PCT/JP2008/060129 2007-05-31 2008-06-02 ピリミドジアゼピノン誘導体 Ceased WO2008149834A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN200880015414A CN101679447A (zh) 2007-05-31 2008-06-02 嘧啶并二氮杂酮衍生物
EP08777080A EP2163554B1 (en) 2007-05-31 2008-06-02 Pyrimidodiazepinone derivative
ES08777080T ES2391549T3 (es) 2007-05-31 2008-06-02 Derivado de Pirimidodiazepinona
JP2009517856A JP5345931B2 (ja) 2007-05-31 2008-06-02 ピリミドジアゼピノン誘導体
CA002689374A CA2689374A1 (en) 2007-05-31 2008-06-02 Pyrimidodiazepinone derivative
US12/602,312 US7998954B2 (en) 2007-05-31 2008-06-02 Pyrimidodiazepinone derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007144731 2007-05-31
JP2007-144731 2007-05-31

Publications (1)

Publication Number Publication Date
WO2008149834A1 true WO2008149834A1 (ja) 2008-12-11

Family

ID=40093650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060129 Ceased WO2008149834A1 (ja) 2007-05-31 2008-06-02 ピリミドジアゼピノン誘導体

Country Status (9)

Country Link
US (1) US7998954B2 (ja)
EP (1) EP2163554B1 (ja)
JP (1) JP5345931B2 (ja)
KR (1) KR20100031586A (ja)
CN (1) CN101679447A (ja)
CA (1) CA2689374A1 (ja)
ES (1) ES2391549T3 (ja)
TW (1) TW200914457A (ja)
WO (1) WO2008149834A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012153796A1 (ja) 2011-05-10 2012-11-15 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
WO2014069626A1 (ja) * 2012-11-01 2014-05-08 協和発酵キリン株式会社 ピリミドジアゼピノン化合物の製造方法
JP2019515039A (ja) * 2016-05-06 2019-06-06 エステベ ファーマシューティカルズ，エセ．アー． 疼痛および疼痛に関連した状態を治療するための新たなテトラヒドロピリミドジアゼピンおよびジヒドロピリドジアゼピン化合物
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877188A1 (en) * 2012-09-19 2014-03-27 F. Hoffmann-La Roche Ag 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
EP2918171A1 (en) * 2014-03-14 2015-09-16 University of Vienna Novel plant growth regulators and their use in modulating organ number
EP3697766A1 (en) * 2017-10-19 2020-08-26 Esteve Pharmaceuticals, S.A. New alkoxyamino compounds for treating pain and pain related conditions
CA3135041A1 (en) 2019-03-26 2020-10-01 Puzzle Medical Devices Inc. Modular mammalian body implantable fluid flow influencing device and related methods
US12383723B2 (en) 2019-10-05 2025-08-12 Puzzle Medical Devices Inc. Mammalian body implantable fluid flow influencing device
KR20250133870A (ko) 2022-11-01 2025-09-09 퍼즐 메디컬 디바이시스 인크. 이식 가능 의료 기기 및 이와 관련된 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
JP2005536507A (ja) * 2002-07-11 2005-12-02 メルク　エンド　カムパニー　インコーポレーテッド ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225917B1 (en) 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
US20080027037A1 (en) 2000-04-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Cyclic compounds
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2001083460A1 (en) * 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Cyclic compounds
CA2479277A1 (en) 2002-03-26 2003-10-02 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7276868B2 (en) * 2004-03-29 2007-10-02 Allred Iii Jimmie B Carbon-fiber laminate musical instrument sound board
TW200804389A (en) * 2006-02-14 2008-01-16 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536507A (ja) * 2002-07-11 2005-12-02 メルク　エンド　カムパニー　インコーポレーテッド ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TEMPEST P. ET AL.: "MCC/SNAr methodology. Part 1: Novel access to a range of heterocyclic cores", TETRAHEDRON LETTERS, vol. 42, no. 30, 23 July 2001 (2001-07-23), pages 4963 - 4968, XP004250155 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012153796A1 (ja) 2011-05-10 2012-11-15 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
JPWO2012153796A1 (ja) * 2011-05-10 2014-07-31 協和発酵キリン株式会社 ピリミドジアゼピノン化合物
US9453021B2 (en) 2011-05-10 2016-09-27 Kyowa Hakko Kirin Co., Ltd. Pyrimidodiazepinone compound
WO2014069626A1 (ja) * 2012-11-01 2014-05-08 協和発酵キリン株式会社 ピリミドジアゼピノン化合物の製造方法
JP2019515039A (ja) * 2016-05-06 2019-06-06 エステベ ファーマシューティカルズ，エセ．アー． 疼痛および疼痛に関連した状態を治療するための新たなテトラヒドロピリミドジアゼピンおよびジヒドロピリドジアゼピン化合物
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体

Also Published As

Publication number Publication date
JPWO2008149834A1 (ja) 2010-08-26
US7998954B2 (en) 2011-08-16
KR20100031586A (ko) 2010-03-23
ES2391549T3 (es) 2012-11-27
EP2163554A4 (en) 2010-12-15
EP2163554A1 (en) 2010-03-17
US20100190775A1 (en) 2010-07-29
CN101679447A (zh) 2010-03-24
CA2689374A1 (en) 2008-12-11
JP5345931B2 (ja) 2013-11-20
EP2163554B1 (en) 2012-08-01
TW200914457A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
WO2009028543A1 (ja) 置換ピラゾール誘導体
PH12012501711A1 (en) [5,6] heterocyclic compound
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
IN2012CN09242A (ja)
WO2009069736A1 (ja) 含窒素化合物
TW200642683A (en) Heterocyclic compound
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008108386A1 (ja) 医薬組成物
WO2009072621A1 (ja) 置換ジヒドロアゾール化合物及び有害生物防除剤
WO2008136444A1 (ja) 縮合複素環誘導体
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2009005152A1 (ja) 新規脂質トリペプチド性ヒドロゲル化剤及びヒドロゲル
NZ596615A (en) Substituted isoquinoline derivative
WO2008096829A1 (ja) ３環系化合物
WO2008126890A1 (ja) ヒドラジド化合物およびそれを含有する有害節足動物防除剤
TW200531683A (en) Aryl- and heteroarylpiperidinecarboxylate derivatives, their preparation and their application in therapeutics
WO2008140099A1 (ja) テトラゾイルオキシム誘導体および植物病害防除剤
WO2009063990A1 (ja) ベンズアゼピノン化合物
MX2010001344A (es) Compuesto de acido fenilacetico.
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
MX2010001566A (es) Derivado de aminopirazolamida.
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
WO2008105526A1 (ja) マクロ環状化合物
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015414.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777080

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2689374

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009517856

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12602312

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008777080

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097027476

Country of ref document: KR

Kind code of ref document: A